(2S)-N1-(3,5-dichlorophenyl)-N2-(9-ethyl-9H-carbazol-3-yl)-4-methylene-1,2-pyrrolidinedicarboxamide | 364073-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2S)-N1-(3,5-dichlorophenyl)-N2-(9-ethyl-9H-carbazol-3-yl)-4-methylene-1,2-pyrrolidinedicarboxamide
• 英文别名: (2S)-1-N-(3,5-dichlorophenyl)-2-N-(9-ethylcarbazol-3-yl)-4-methylidenepyrrolidine-1,2-dicarboxamide
• CAS: 364073-94-9
• 化学式: C₂₇H₂₄Cl₂N₄O₂
• 分子量: 507.419
• InChiKey: FIDHDDQIFIYGBE-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-Boc-4-亚甲基-L-脯氨酸 、 3,5-二氯苯异氰酸酯 、 3-氨基-9-乙基咔唑 生成 (2S)-N1-(3,5-dichlorophenyl)-N2-(9-ethyl-9H-carbazol-3-yl)-4-methylene-1,2-pyrrolidinedicarboxamide
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives

  摘要：

  本发明涉及式I的吡咯烷衍生物。所述化合物优选用作药物活性化合物。具体而言，式I的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别地，本发明涉及显示 oxytocin 受体实质调节作用，特别是拮抗剂活性的吡咯烷衍生物。更优选地，所述化合物在治疗和/或预防由 oxytocin 介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新的吡咯烷衍生物以及其制备方法。其中，X选自CR6R7、NOR6、NNR6R7组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2—、—SO2NH—、—CH2—组成的群；B是一个—C═O)—NR8R9或表示为具有式的杂环残基 其中Q是NR10、O或S；n是选择为0、1或2的整数；Y、Z和E与它们附着的2个碳原子一起形成一个5-6元杂芳基或杂环芳基环。

  公开号：

  US20080167318A1

文献信息

• Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：US07018988B2

  公开（公告）日：2006-03-28

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2—, —SO2NH—; —CH2—; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5–6 membered aryl or heteroaryl ring.

  本发明涉及一种新的取代吡咯烷衍生物，其化学式为（I）。所述化合物适用于作为药物活性化合物。具体而言，化学式（I）的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多聚谷氨酸链相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用途。所述吡咯烷衍生物显示出对细胞死亡促进剂Bax和/或导致Bax激活通路的调节作用，尤其是下调作用，甚至具有抑制作用，因此可以阻止细胞色素（c）的释放。本发明还涉及新的药物活性取代吡咯烷衍生物以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—（C═O）—、—（C═O）—O—、—C（═NH）—、—（C═O）—NH—、—（C═S）—NH、—SO2—、—SO2NH—；—CH2—；B是一个—（C═O）—NR<8>R<9>基团或代表具有式（II）的杂环残基，其中Q为NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳原子一起形成一个5-6环芳基或杂环芳基。
• US7018988B2
  申请人：——

  公开号：US7018988B2

  公开（公告）日：2006-03-28
• US7211601B2
  申请人：——

  公开号：US7211601B2

  公开（公告）日：2007-05-01
• Pharmaceutically active pyrrolidine derivatives
  申请人：——

  公开号：US20030212012A1

  公开（公告）日：2003-11-13

  The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。